Continuation transcranial direct current stimulation for the prevention of relapse in major depression

Martin, Donel; Alonzo, Angelo; Ho, Kerrie-Anne; Player, Michael J.; Mitchell, Philip B.; Sachdev, Perminder S.; Loo, Colleen

doi:10.1016/j.jad.2012.10.012

Cited by 71 publications

(46 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In other reviews of tDCS and depression, the odds ratio for (OR) favorable symptom response was 1.63; (95% CI = 1.26-2.12] and the OR for remission was 2.50 (95% CI = 1.26-2.49) (64). When an acute course of tDCS was followed by weekly to fortnightly maintenance tDCS sessions, the cumulative probability to avoid relapse was of 83.7% at 3 months, and 51.1% at 6 months (67). When Major Depressive Disorder (MDD) and Bipolar Depressive Disorder (BDD) were examined separately, five sessions of anodal stimulation induces a beneficial effect that persists at one week and one month in both groups (3).…”

Section: Efficacymentioning

confidence: 99%

Regulatory considerations for the clinical and research use of transcranial direct current stimulation (tDCS): Review and recommendations from an expert panel

Fregni

Nitsche

Loo

et al. 2014

Clinical Research and Regulatory Affairs

224

161

View full text Add to dashboard Cite

The field of transcranial electrical stimulation (tES) has experienced significant growth in the past 15 years. One of the tES techniques leading this increased interest is transcranial direct current stimulation (tDCS). Significant research efforts have been devoted to determining the clinical potential of tDCS in humans. Despite the promising results obtained with tDCS in basic and clinical neuroscience, further progress has been impeded by a lack of clarity on international regulatory pathways. We therefore convened a group of research and clinician experts on tDCS to review the research and clinical use of tDCS. In this report, we review the regulatory status of tDCS, and we summarize the results according to research, off-label and compassionate use of tDCS in the following countries: Australia, Brazil, France, Germany, India, Iran, Italy, Portugal, South Korea, Taiwan and United States. Research use, off label treatment and compassionate use of tDCS are employed in most of the countries reviewed in this study. It is critical that a global or local effort is organized to pursue definite evidence to either approve and regulate or restrict the use of tDCS in clinical practice on the basis of adequate randomized controlled treatment trials.

show abstract

Section: Efficacymentioning

confidence: 99%

Regulatory considerations for the clinical and research use of transcranial direct current stimulation (tDCS): Review and recommendations from an expert panel

Fregni

Nitsche

Loo

et al. 2014

Clinical Research and Regulatory Affairs

224

161

View full text Add to dashboard Cite

show abstract

“…Only two follow-up studies were carried out hitherto 44,45 with relatively poor results, with a relapse rate of around 50% in six months. We propose that the same strategies under research for rTMS could be employed here, namely more frequent stimulation sessions and use of antidepressant drugs during the maintenance phase.…”

Section: Discussionmentioning

confidence: 99%

Novel neurotherapeutics in psychiatry: use and rationale of transcranial direct current stimulation in major depressive disorder

Moffa¹,

Valiengo²,

Shiozawa³

et al. 2014

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

Background: Transcranial direct current stimulation (tDCS) is a novel non-pharmacological intervention being investigated for the treatment of major depressive disorder (MDD). Objective: To perform an updated review of tDCS for MDD. Method: Systematic review in Medline/PubMed and other databases of all clinical studies evaluating the clinical efficacy of tDCS in MDD, from the first date available to December/2013. Results: Out of 55 articles, 24 were included, being 6 open-label studies; 8 randomized, double-blind, sham-controlled trials; 2 follow-up studies; 2 meta-analyses and 6 case reports. We observed an improvement of 20-40% in depressive symptoms, being slightly better in open studies. Five randomized clinical trials displayed positive results. The meta--analyses presented mixed results; although none included the study of that represents almost 50% of the evaluated sample. Open-label studies and case reports also investigated tDCS in bipolar depression, post-stroke depression and employed different parameters of stimulation. Discussion: TDCS is a novel, promising treatment for MDD. Definite evidence from large, ongoing clinical trials will be available in the next years.

show abstract

“…Electric field maps corresponding to these montages have been previously modelled . For all studies tDCS was administered according to the safety procedures previously described , and side-effects during and following every treatment were recorded (Martin et al, 2013).…”

Section: Participantsmentioning

confidence: 99%

Pre-treatment letter fluency performance predicts antidepressant response to transcranial direct current stimulation

Martin

Yeung

Loo

2016

Journal of Affective Disorders

Self Cite

View full text Add to dashboard Cite

Continuation transcranial direct current stimulation for the prevention of relapse in major depression

Cited by 71 publications

References 24 publications

Regulatory considerations for the clinical and research use of transcranial direct current stimulation (tDCS): Review and recommendations from an expert panel

Regulatory considerations for the clinical and research use of transcranial direct current stimulation (tDCS): Review and recommendations from an expert panel

Novel neurotherapeutics in psychiatry: use and rationale of transcranial direct current stimulation in major depressive disorder

Pre-treatment letter fluency performance predicts antidepressant response to transcranial direct current stimulation

Contact Info

Product

Resources

About